Related Experiment Video
Updated: Jun 13, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
983
DeepCGAN: early Alzheimer's detection with deep convolutional generative adversarial networks.
Imad Ali1, Nasir Saleem2, Musaed Alhussein3
1Department of Computer Science, University of Swat, Swat, KP, Pakistan.
Frontiers in Medicine
|September 13, 2024
Summary
This study introduces DeepCGAN, a novel deep learning model for early Alzheimer's disease detection. DeepCGAN achieves 97.32% accuracy, outperforming existing methods for timely diagnosis.
Area of Science:
- Medical Imaging
- Artificial Intelligence
- Neuroscience
Background:
- Alzheimer's disease (AD) is a leading cause of dementia, necessitating early detection for effective intervention.
- Detecting early-stage AD via magnetic resonance imaging (MRI) is challenging due to subtle physiological differences.
- Current diagnostic methods often lack the sensitivity for subtle, early-stage AD indicators.
Purpose of the Study:
- To propose a Deep Convolutional Generative Adversarial Network (DeepCGAN) for enhanced early-stage Alzheimer's disease detection.
- To leverage unsupervised generative models to augment limited medical imaging datasets for improved AD classification.
- To improve the accuracy and robustness of early AD detection using advanced deep learning techniques.
Main Methods:
- Developed a Deep Convolutional Generative Adversarial Network (DeepCGAN) employing an encoder-decoder generator and a discriminator with a similar encoder structure.
- Utilized generative adversarial network (GAN) principles to expand dataset size and diversity for unsupervised learning.
- Integrated a softmax classifier in the final dense layer for AD classification based on cognitive data.
Main Results:
- The proposed DeepCGAN model achieved a high accuracy rate of 97.32% in detecting early-stage Alzheimer's disease.
- Significantly outperformed contemporary state-of-the-art models, including Adaptive Voting, ResNet, AlexNet, GoogleNet, Deep Neural Networks, and Support Vector Machines.
- Demonstrated superior performance and generalization capabilities compared to traditional and current methods.
Conclusions:
- DeepCGAN enhances early AD detection accuracy and robustness through improved dataset diversity and advanced GAN techniques.
- The model's high performance suggests significant potential for improving patient outcomes via timely diagnosis and intervention.
- This study highlights the efficacy of DeepCGAN as a powerful tool for early Alzheimer's disease detection in medical imaging.
Related Concept Videos
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170

